X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (87) 87
hematology (57) 57
index medicus (51) 51
male (47) 47
middle aged (47) 47
female (46) 46
aged (44) 44
multiple myeloma - drug therapy (44) 44
adult (43) 43
bortezomib (41) 41
multiple myeloma (35) 35
oncology (33) 33
treatment outcome (28) 28
antineoplastic combined chemotherapy protocols - therapeutic use (24) 24
aged, 80 and over (21) 21
antineoplastic agents - therapeutic use (20) 20
dexamethasone (20) 20
hematology, oncology and palliative medicine (20) 20
recurrence (20) 20
immunology (19) 19
transplantation (19) 19
dexamethasone - administration & dosage (17) 17
thalidomide - administration & dosage (17) 17
thalidomide - analogs & derivatives (17) 17
therapy (17) 17
article (16) 16
multiple myeloma - pathology (16) 16
multiple myeloma - therapy (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
multiple myeloma - mortality (15) 15
stem-cell transplantation (13) 13
survival analysis (13) 13
disease-free survival (12) 12
dose-response relationship, drug (12) 12
lenalidomide (12) 12
survival (12) 12
apoptosis (11) 11
cancer (11) 11
combination (11) 11
drug resistance, neoplasm (11) 11
prognosis (11) 11
transplantation, homologous (11) 11
abridged index medicus (10) 10
boronic acids - administration & dosage (10) 10
boronic acids - therapeutic use (10) 10
chemotherapy (10) 10
pyrazines - administration & dosage (10) 10
pyrazines - therapeutic use (10) 10
research (10) 10
thalidomide (10) 10
animals (9) 9
antineoplastic agents - adverse effects (9) 9
bone-marrow-transplantation (9) 9
combination therapy (9) 9
dexamethasone - adverse effects (9) 9
disease progression (9) 9
drug administration schedule (9) 9
hematopoietic stem cell transplantation (9) 9
multiple myeloma - diagnosis (9) 9
multiple-myeloma (9) 9
survival rate (9) 9
antineoplastic combined chemotherapy protocols - administration & dosage (8) 8
care and treatment (8) 8
hemic and lymphatic diseases (8) 8
thalidomide - adverse effects (8) 8
bone marrow (7) 7
cell line, tumor (7) 7
cells (7) 7
follow-up studies (7) 7
graft vs host disease - prevention & control (7) 7
lenalidomide plus dexamethasone (7) 7
salvage therapy (7) 7
young adult (7) 7
boronic acids - adverse effects (6) 6
carfilzomib (6) 6
clinical trials and observations (6) 6
health aspects (6) 6
hematopoietic stem cell transplantation - methods (6) 6
mice (6) 6
multiple myeloma - complications (6) 6
multiple myeloma - genetics (6) 6
multiple myeloma - metabolism (6) 6
neoplasm recurrence, local - drug therapy (6) 6
neoplasm staging (6) 6
newly-diagnosed myeloma (6) 6
plus dexamethasone (6) 6
proteasome inhibitor (6) 6
pyrazines - adverse effects (6) 6
relapse (6) 6
retrospective studies (6) 6
single-agent carfilzomib (6) 6
thalidomide - therapeutic use (6) 6
time factors (6) 6
transplantation, autologous (6) 6
antineoplastic agents - administration & dosage (5) 5
cytogenetics (5) 5
dexamethasone - therapeutic use (5) 5
drug therapy (5) 5
drug-resistance (5) 5
graft vs host disease - etiology (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 112 - 121
Summary Background Clonal haemopoiesis of indeterminate potential (CHIP) is an age-associated genetic event linked to increased risk of primary haematological... 
Hematology, Oncology and Palliative Medicine | ADJUVANT CHEMOTHERAPY | BREAST-CANCER | COLON-CANCER | VARIANTS | ONCOLOGY | FORMAT | SEQUENCE | MUTATIONS | LEUKEMIA | OUTCOMES | MYELODYSPLASTIC SYNDROMES | Clone Cells - drug effects | Prognosis | Follow-Up Studies | Humans | Leukemia, Myeloid, Acute - epidemiology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Case-Control Studies | Incidence | Neoplasms, Second Primary - chemically induced | Myelodysplastic Syndromes - chemically induced | Aged, 80 and over | Female | Neoplasms, Second Primary - genetics | High-Throughput Nucleotide Sequencing - methods | Leukemia, Myeloid, Acute - chemically induced | Florida - epidemiology | Risk Factors | Hematopoiesis - genetics | Survival Rate | Mutation - genetics | Myelodysplastic Syndromes - epidemiology | Clone Cells - metabolism | Neoplasms - drug therapy | Neoplasms, Second Primary - diagnosis | Neoplasms, Second Primary - epidemiology | Myelodysplastic Syndromes - diagnosis | Clone Cells - pathology | Leukemia, Myeloid, Acute - diagnosis | Aged | Biomarkers, Tumor - genetics | Myelodysplastic Syndromes - genetics | Neoplasm Staging | Neoplasms - pathology | Leukemia, Myeloid, Acute - genetics | Care and treatment | Chemotherapy | Oncology, Experimental | Mortality | Aged patients | Research | Epidemiology | Cancer | Development and progression
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2003, Volume 348, Issue 26, pp. 2609 - 2617
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2009, Volume 27, Issue 34, pp. 5713 - 5719
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 07/2019, Volume 94, Issue 7, pp. 794 - 802
Twice‐weekly carfilzomib (27 mg/m 2 ) with lenalidomide‐dexamethasone (KRd) is a standard‐of‐care in relapsed or refractory multiple myeloma (RRMM). This phase... 
Carfilzomib | Relapse | Dexamethasone | Multiple myeloma | Diseases | Toxicity | Response rates
Journal Article
Journal Article